NHS Information Standards Board
|
|
- Cody Hubbard
- 6 years ago
- Views:
Transcription
1 NHS Information Standards Board DSC Notice: 06/2001* Date of Issue: March 2001 Subject: Data requirement for the production of casemix adjusted Reference Costs for Chemotherapy interventions. Implementation date: 01 April 2001 to commence preparation. 01 October 2001 for data collection/costing. DATA SET CHANGE CONTROL PROCEDURE This paper gives notification of changes to be included in the NHS Data Dictionary, the NHS Data Manual and the NHS CDS Manual in due course. Summary of change: Mandatory collection and data flow of Chemotherapy HRGs Summary of impact: Extension of data collection and expansion of dataflows. Change Proposal Reference No: 02/01 The NHS Information Standards Board (ISB), established by the NHS Information Authority, is responsible for approving information standards. The NHS ISB is supported by the Management Information Standards Board, Clinical Data Standards and Technical Standards sub-boards. *The DSCN Number Format has been changed to denote the new arrangements as follows: sequence number/year of issue (ccyy). The service identifier and service sequence number are redundant owing to changes in practice and have been removed. The packaging of standards documentation is under review. Any changes will be notified in due course. Please address enquiries about this DSCN to the Data Standards Team, NHS Information Authority, Aqueous II, Aston Cross, Rocky Lane, Birmingham, B6 5RQ Tel: or to the nominated enquiry point. Data Set Change Notices are located on the Internet in the Electronic Library at and on the NHSnet at
2 Reference: CP 02/01 version 1.2 DATA SET CHANGE NOTICE 06/2001 Subject: Type of Change: Data requirement for the production of casemix adjusted Reference Costs for chemotherapy interventions. i. Mandatory collection of a list of Chemotherapy HRGs, (see Appendix 1) ii. Introduction of an annual data flow of these aggregated data items from Providers to the NHS Executive Headquarters Reason for Change: To introduce Chemotherapy HRGs required to support casemix adjusted costs for the purposes of the National Schedule of Reference Costs (NSRC). Effective Date: Mandatory collection of Chemotherapy HRGs from 1 st October 2001 for the 2001/02 financial year. This six months data to be annualised for the reference cost submission to be submitted by the 30 th June The six months from the 1 st April to 30 th September 2001 to be used by the service as a lead-in / preparation period before commencing the mandatory collection of Chemotherapy HRGs on 1 st October Introduction: 1. The new NHS white paper made it clear that Trusts will be required to publish their costs on a consistent basis and the data will be published in a National Schedule of Reference Costs. This DSCN: i. mandates the collection of the list of Chemotherapy HRGs as given in Appendix 1; and ii. extends the current annual mandatory data flow of reference costs to include these aggregated Chemotherapy HRGs from NHS Trusts to the NHS Executive Headquarters. This will then meet MS (H) requirements in respect of the rollout of the NSRC and facilitate the benchmarking of services. In addition this information will be used in determining efficiency targets for the NHS, and supporting the monitoring of performance against National Service Frameworks. Page 2 of 9
3 Background: 2. Cost information on chemotherapy is incorporated in final accounts in global terms. This is not suitable for reference costs nor does it allow for the differing complexity of activity to be adjusted for in setting efficiency targets. To meet the timetable agreed with MS (H) a consistent dataset needs to be available to allow costed HRG information to be included in the reference cost information from June Chemotherapy services are one of the major areas of activity provided by acute NHS Trusts, hence the requirement to include meaningful activity costs in the National Schedule as soon as possible to meet ministerial commitments. 3. For the June 2001 NSRC returns Trusts are required to submit costed chemotherapy data on interim groupings based on the more common drug regimens and the site of the cancer itself. This supports the direction of travel taken by the work of clinicians on developing more substantive groupings. They assist the providers of these services to begin separately identifying the high costs of chemotherapy for reference costs purposes as an interim step to the introduction of more detailed groupings of Chemotherapy HRGs for the 2002 NSRC returns. 4. In pursuit of more sophisticated costing, an analytical base for developing Chemotherapy HRGs was established on a series of target chemotherapy protocols in a pilot study. The pilot study involved: 4 NHS Trusts - identifying individual treatment components for 30 patients per protocol - attributing costs to each component - identifying the relevant data items involved, casenote search, scrutiny of pharmacy and other departmental systems. 5. A report on the analysis of this first tranche of data recommended that further data be collected to extend and strengthen the analysis to cover all main protocols used to treat solid tumours. This pilot study involved a new series of pilot sites of an additional 4 NHS Trusts further validating the initial research. 6. It was agreed at the outset that the analysis should support a straightforward HRG structure of chemotherapy treatments, which were clinically meaningful. Comparative analysis of the data assisted in identifying an HRG structure, allocating an HRG to a programme of chemotherapy treatment, based on the named drug protocol and tumour site. 7. Given the complexities of leukaemia and myeloma treatments, it is intended that Chemotherapy interventions for this condition are covered under the auspices of a separate project. It is planned that these will be included in the National Schedule of Reference Costs to meet ministerial timescales and to support developments detailed in the recent NHS National Plan. Page 3 of 9
4 8. HRG development is well supported by the clinical professions and their appropriate professional organisations. 9. Further details on Chemotherapy HRG assignment/costing requirements will be found in the Chemotherapy Definitions Manual (A Chemotherapy Definitions Manual will be posted to the NHS Information Authority, Casemix Programme website nww.casemix.nhsia.nhs.uk during May 2001 for downloading as a pdf file) and the 2001 Costing Guidance. New Arrangements: 10. This DSCN mandates the collection of the prospective directly assigned data items listed at Appendix 1 and their submission on an annual basis to the NHS Executive. This builds upon the interim groupings detailed in the 2001 Costing Guidance. Argument: 11. In implementing this aspect of the White Paper, the National Costing Strategy Group (NCSG) has been given lead responsibility for the development of reference costs including the National Schedule of Reference Costs (NSRC) and associated information including the National Reference Cost Index (NRCI). This is used as the basis of setting efficiency targets on an annual basis. 12. This change builds on the national costing initiative that falls within the remit of this Costing Group. Efficiency and performance colleagues have therefore supported the roll out of casemix adjusted reference costs across all parts of the acute sector as quickly as possible. 13. Approval was given by ROCR in November 1997 to develop an HRG database for acute services in line with a timetable agreed by MS (H). This included approval of an annual collection exercise (undertaken in June each year) by electronic medium. The June 2001 collection will cover all surgical and medical inpatient and day case activity, Accident & Emergency, Radiotherapy, consultant-led and nurse-led outpatient activity for Ophthalmology, Dermatology, Gynaecology, General Surgery (Surgical Gastroenterology, Vascular Surgery, Breast & Endocrine Surgery), Rheumatology, Trauma & Orthpaedics, Urology, Medical Gastroenterology and Cardiology. Where HRGs are currently not available, other activity measures have been used e.g. bed/cot days for critical care services, clients for community nursing services and new and follow-up costs for outpatient specialties not already mandated. The interim chemotherapy groupings identified in the 2000 Costing Guidance and collected as part of the 2001 Reference Cost Collection will be replaced in the NSRC by casemix-adjusted HRG costs from June The use of chemotherapy has increased markedly during the 1990s with a concomitant rise in expenditure related both to the use of cytotoxic drugs per se and to the supportive services needed by patients undergoing chemotherapy (e.g. inpatient and outpatient care; investigations; treatments for side-effects and complications). Page 4 of 9
5 15. The increase in chemotherapy usage and expenditure can be attributed to a number of factors: Wider usage of chemotherapy in patient groups where treatment was already established before 1990 (e.g. breast cancer; colorectal cancer). Extension of the use of chemotherapy to a wider range of tumour types. Introduction of expensive new anticancer agents (e.g. paclitaxel, docetaxel). Introduction of new supportive care treatments (e.g. 5HT 3 antiemetics; colony stimulating factors). 16. There is currently no standardised method for recording chemotherapy activity across the UK. Cancer Registries normally only collect information on anticancer treatments delivered within six months of diagnosis, thus missing many patients who receive chemotherapy late in the course of the disease. Information on chemotherapy recorded by Cancer Registries is usually limited to a simple Yes/No item, without (for example) recording the type of chemotherapy used or its duration. Information held on hospital patient administration systems is frequently based on contracting currencies, which vary across the country. Detailed data are collected within some oncology departments, but are unlikely to yield comparable data due to a lack of agreed definitions. 17. Agreed Chemotherapy HRG definitions and dataset to support them will have several benefits, including: promoting more robust recording of information Casemix specific information for use in performance management, service planning and national, regional and local benchmarking initiatives. more clinically meaningful activity base for cost comparison. Clearance: 18. The NSRC principles and acute services roll out time-scales have been approved by MS (H) following recommendations by the former Financial Issues Group (multidisciplinary) who were responsible for the co-ordination of the implementation of the financial aspects of the White Paper. This responsibility has now been passed to various constituent Groups such as the National Costing Strategy Group. As part of the process for reference costs a consultation exercise was undertaken with the NHS following ministerial approval copies of the consultation document were issued and 150 (10% rate) responses were received. 19. The responses were supportive of the principles and processes being adopted; 74.5% of NHS Trusts and 85.7% of Health Authorities who responded were supportive. In addition, letters of support were received from the BMA, Unison, National Consumer Council and several Community Health Councils. Since this time, representations have continued to be received for widening the scope of reference costs, developing measures Page 5 of 9
6 that reflect changes in clinical practice and technological developments and support the NHS business agenda generally. 20. Discussions with representatives of ROCR confirmed that the original approval given in November 1997 covers the acute services included within this and previous notices. 21. Development of HRGs are supported by those needing to monitor performance against National Service Frameworks as this will start to allow performance to be monitored across a wider range of care which constitute a more rounded view of health care delivery. In addition, the NHS members of the National Costing Strategy Group, HFMA and Teaching Hospitals Trusts Finance Group have given support. 22. The NHS Information Authority (Population Health and Service Management Information Area of Work) also supports this development. 6. Conclusion: 23. This change mandates the collection of the list of Chemotherapy HRGs listed in Appendix This will allow casemix adjusted activity and cost data to be included in the NSRC, National Reference Cost Index and will be used to support the development of more sensitive efficiency measures. 25. Work will be undertaken to complete the development of chemotherapy treatments for leukaemia and myeloma HRGs and those will be the subject of a future change proposal. Page 6 of 9
7 Additional Information: For additional information on technical and developmental aspects of these HRGs please contact: Virginia Jordan Project Manager NHS Information Authority Population Health & Service Management Highcroft Romsey Road Winchester SO22 5DH Tel: Fax: Website: nww.casemix.nhsia.nhs.uk Or For additional information on costing and data collection aspects of these HRGs please contact: Anne Arnold or Paula Monteith FD-CSD Department of Health Quarry House Quarry Hill Leeds LS2 7UE Fax: or Tel: Page 7 of 9
8 Appendix 1 Chemotherapy: HRG Labels (Version 3.1) HRG X01 X02 X03 X04 X05 X06 X07 X08 X09 X10 X11 X12 X13 X14 X15 X16 X17 X18 X19 X20 X21 X22 X23 X24 X25 X26 X27 X28 X29 X30 Description Breast Cancer Chemotherapy CMFs Breast Cancer Chemotherapy Anthracycline Breast Cancer Chemotherapy Vinorelbine Breast Cancer Chemotherapy Taxane Breast Cancer Chemotherapy Trastuzumab Breast Cancer Chemotherapy Other Colorectal Cancer Chemotherapy Fluorouracil Bolus Colorectal Cancer Chemotherapy Fluorouracil (48hr infusion) Colorectal Cancer Chemotherapy Fluorouracil continuous infusion Colorectal Cancer Chemotherapy Irinotecan Colorectal Cancer Chemotherapy Oxaliplatin Colorectal Cancer Chemotherapy Other Lung Small Cell Cancer Chemotherapy CAV Lung Small Cell Cancer Chemotherapy CAE Lung Small Cell Cancer Chemotherapy Platin based regimens Lung Small Cell Cancer Chemotherapy VICE Lung Small Cell Cancer Chemotherapy Other Lung Non Small Cell Cancer Chemotherapy MIC or MVP Lung Non Small Cell Cancer Chemotherapy Single Agent Vinorelbine Lung Non Small Cell Cancer Chemotherapy Single Agent Gemcitabine Lung Non Small Cell Cancer Chemotherapy Vinorelbine, Gemcitabine in combination Lung Non Small Cell Cancer Chemotherapy Docetaxel Lung Non Small Cell Cancer Chemotherapy Other Ovarian Cancer Chemotherapy Single Agent Carboplatin Ovarian Cancer Chemotherapy Paclitaxel Ovarian Cancer Chemotherapy Other Stomach Cancer Chemotherapy ECF Stomach Cancer Chemotherapy Other Oesophageal Cancer Chemotherapy Cisplatin and Fluorouracil Oesophageal Cancer Chemotherapy Other Page 8 of 9
9 X31 X32 X33 X34 X35 X36 X37 X38 X39 X40 X41 X42 Bladder Cancer Chemotherapy Platin based regimens Bladder Cancer Chemotherapy Other Testicular Cancer Chemotherapy BEP Testicular Cancer Chemotherapy POMBACE Testicular Cancer Chemotherapy Other Cervical Cancer Chemotherapy Platin based regimens Cervical Cancer Chemotherapy Other Non Hodgkins Lymphoma Cancer Chemotherapy CHOP Non Hodgkins Lymphoma Cancer Chemotherapy Other Hodgkins Disease Cancer Chemotherapy ABVD Hodgkins Disease Cancer Chemotherapy Other Other Solid Tumour Cancer Chemotherapy Special Notes 1. The Chemotherapy HRGs are identified by tumour site and will be assigned to each programme of chemotherapy. The HRG assigned will be based on the regimen prescribed for that programme. A programme can be made up of many cycles, the cycle being the pattern of drug administered for a single regimen. The HRGs will be assigned prospectively to that programme of treatment at cycle1,day1. 2. The Chemotherapy HRGs have received the endorsement of the National Costing Strategy Group, the Information Standards Board, the Management Information Standards Board, the Chemotherapy Clinical Working Group, and the Joint Collegiate Committee for Oncology. 3. Further details on Chemotherapy HRG assignment/costing requirements will be found in the Chemotherapy Definitions Manual (A Chemotherapy Definitions Manual will be posted to the NHS Information Authority, Casemix Programme website nww.casemix.nhsia.nhs.uk during May 2001 for downloading as a pdf file) and the 2001 Costing Guidance. Page 9 of 9
STATISTICAL PRESS NOTICE NHS REFERRAL TO TREATMENT (RTT) WAITING TIMES DATA JANUARY 2013
STATISTICAL PRESS NOTICE NHS REFERRAL TO TREATMENT (RTT) WAITING TIMES DATA JANUARY 2013 Data are published on consultant-led Referral to Treatment (RTT) waiting times for patients who were treated during
More informationWELSH INFORMATION GOVERNANCE & STANDARDS BOARD
WELSH INFORMATION GOVERNANCE & STANDARDS BOARD DSC Notice: DSCN 2011-04 Date of Issue: 7 TH June 2011 Ministerial / Official Letter: Sponsor: Subject: Replacement of KC60 Diagnostic and Services Codes
More informationto improve the collection and publication of data on chemotherapy activity, outcomes and costs, the chemotherapy dataset will be introduced
6.19... to improve the collection and publication of data on chemotherapy activity, outcomes and costs, the chemotherapy dataset will be introduced in April 2012 and this should provide commissioners,
More informationClinical Commissioning Policy: Chemotherapy Algorithms for Adults and Children. January 2013 Reference: NHS England XXX/X/X.
Clinical Commissioning Policy: Chemotherapy Algorithms for Adults and Children January 2013 Reference: NHS England XXX/X/X England 1 NHS England Clinical Commissioning Policy: Chemotherapy Algorithms for
More informationSTATISTICAL PRESS NOTICE NHS REFERRAL TO TREATMENT (RTT) WAITING TIMES DATA MAY 2011
STATISTICAL PRESS NOTICE NHS REFERRAL TO TREATMENT (RTT) WAITING TIMES DATA MAY 2011 Main Points Data are published on consultant-led Referral to Treatment (RTT) waiting times for patients who were treated
More informationOPCS Classification of Interventions and Procedures Version 4.6 (April 2011)
Chemotherapy Regimens Clinical Coding Guidance OPCS-4.6 Version 1.0 Programme Sub Programme Data Standards & Products Clinical Classifications Document Record ID Key NPFIT-SHR-SHI-0318.01 Programme Director
More informationWaiting Times for Suspected and Diagnosed Cancer Patients
Waiting Times for Suspected and Diagnosed Cancer Patients 2015-16 Annual Report Waiting Times for Suspected and Diagnosed Cancer Patients 1 Waiting Times for Suspected and Diagnosed Cancer Patients Prepared
More informationCommissioning Cancer Services. Andy McMeeking RCGP/NCIN Primary Care Workshop, 13 th February 2013
Commissioning Cancer Services Andy McMeeking RCGP/NCIN Primary Care Workshop, 13 th February 2013 The Health & Social Care Bill (27 th March 2012) Two New Organisations NHS Commissioning Board (NHS CB)
More informationNational Cancer Peer Review Sarcoma. Julia Hill Acting Deputy National Co-ordinator
National Cancer Peer Review Sarcoma Julia Hill Acting Deputy National Co-ordinator Improving Outcomes Guidance The Intentions of Improving Outcomes for People with Sarcoma Changes in the provision of care
More informationCancer Improvement Plan Update. September 2014
Cancer Improvement Plan Update September 2014 1 Contents Page 1. Introduction 3 2. Key Achievements 4-5 3. Update on Independent Review Recommendations 6-13 4. Update on IST Recommendations 14-15 5. Update
More informationAligning the Publication of Performance Data Statistics Consultation
Aligning the Publication of Performance Data Statistics Consultation NHS England INFORMATION READER BOX Directorate Medical Commissioning Operations Patients and Information Nursing Trans. & Corp. Ops.
More informationCancer Outcomes and Services Dataset: Implications for clinical teams
Cancer Outcomes and Services Dataset: Implications for clinical teams Mick Peake Clinical Lead, NCIN National Clinical Lead, NHS Cancer Improvement Consultant & Senior Lecturer in Respiratory Medicine,
More informationSandwell Safeguarding Adults Board. ANNUAL REPORT 2016/2017 Executive Summary
Sandwell Safeguarding Adults Board SSAB@SSAdultsBoard ANNUAL REPORT 2016/2017 Executive Summary SEE SOMETHING DO SOMETHING Safeguarding is everyone s business SEE SOMETHING If you are concerned that an
More informationRTT Exception Report
Appendix 3 RTT Exception Report 1. Purpose To provide a summary of factors impacting on 18 week RTT performance and a revised forecast of red rated performance for Quarter 2 2015/16 for the admitted pathway.
More informationChemotherapy Training and Assessment Policy. For Medical Prescribers and Pharmacy Verifiers
Chemotherapy Training and Assessment Policy For Medical Prescribers and Pharmacy Verifiers For approvals and version control see Document Management Record on page 6 Doc Ref: AngCN-CCG-C36 Approved and
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Herceptin) Reference Number: ERX.SPA.42 Effective Date: 07.01.16 Last Review Date: 05/17 Line of Business: Commercial [Prescription Drug Plan] Revision Log See Important Reminder at the
More informationStatistical Press Notice NHS referral to treatment (RTT) waiting times data November 2016
Statistical Press Notice NHS referral to treatment (RTT) waiting times data November 2016 NHS England released statistics today on referral to treatment (RTT) waiting times for consultant-led elective
More informationCANCER IN SCOTLAND: ACTION FOR CHANGE The structure, functions and working relationships of Regional Cancer Advisory Groups
CANCER IN SCOTLAND: ACTION FOR CHANGE The structure, functions and working relationships of Regional Cancer Advisory Groups Introduction/Background 1. Our National Health: A Plan for action, a plan for
More informationCancer and Data in the New NHS May Di Riley, Director Clinical Outcomes
Cancer and Data in the New NHS May 2011 Di Riley, Director Clinical Outcomes Overarching NHS context Financial constraints White Paper GP Commissioning/Commissioning Board Public Health England National
More informationProgress in improving cancer services and outcomes in England. Report. Department of Health, NHS England and Public Health England
Report by the Comptroller and Auditor General Department of Health, NHS England and Public Health England Progress in improving cancer services and outcomes in England HC 949 SESSION 2014-15 15 JANUARY
More informationIntegrated Cancer Services Action Plan. Colchester Hospital University NHS Foundation Trust 31 March 2014
Integrated Cancer Services Action Plan Colchester Hospital University NHS Foundation Trust 31 March KEY Implemented, clearly evidenced and externally approved On Track to deliver Some issues narrative
More informationWELSH INFORMATION STANDARDS BOARD
WELSH INFORMATION STANDARDS BOARD DSC Notice: DSCN 2018 / 06 Date of Issue: 8 th August 2018 Welsh Health Circular / Official Letter: (2015) 053 Subject: CT Maturity Matrix Sponsor: Chris Newbrook, Head
More informationWork Programme/Service Delivery Plan 2010/2013
Essex and East Suffolk Gynaecological Cancer Network Site Specific Group Work Programme/Service Delivery Plan 2010/2013 Version Number 1.2 Author Members of the NSSG Date Written June 2010 Reviewed May
More informationStatistical Press Notice NHS referral to treatment (RTT) waiting times data July 2018
Thursday 13 September 2018 Statistical Press Notice NHS referral to treatment (RTT) waiting times data July 2018 NHS England released statistics today on referral to treatment (RTT) waiting times for consultant-led
More informationCancer Outcomes and Services Dataset. What is COSD? Skin Cancers Workshop October 2012
Cancer Outcomes and Services Dataset What is COSD? Skin Cancers Workshop October 2012 17 years ago......cancer registration and careful monitoring of treatment and outcomes are essential... Calman-Hine
More informationReferral to treatment consultant-led waiting times
Referral to treatment consultant-led waiting times How to Measure DH INFORMATION READER BOX Policy Clinical Estates HR / Workforce Commissioner Development IM & T Management Provider Development Finance
More informationFrom the Permanent Secretary and HSC Chief Executive
From the Permanent Secretary and HSC Chief Executive Dr Andrew Murrison MP Chair, N. Ireland Affairs Committee Committee Office House of Commons LONDON SW1A 0AA northircom@parliament.uk Castle Buildings
More informationProgress Report: Health Care Quality Indicators Project. Meeting of OECD Health Data National Correspondents, 8 October, 2009, Paris
Progress Report: Health Care Quality Indicators Project Meeting of OECD Health Data National Correspondents, 8 October, 2009, Paris Project Objectives WHAT are the differences in quality? WHY do these
More informationA themed review of patient safety incidents involving anti-cancer medicines 1 November June 2008
A themed review of patient safety incidents involving anti-cancer medicines 1 November 2003 30 June 2008 October 2010 Executive Summary National Patient Safety Agency 2010. Copyright and other intellectual
More informationNational Cancer Programme. Work Plan 2014/15
National Cancer Programme Work Plan 2014/15 Citation: Ministry of Health. 2014. National Cancer Programme: Work Plan 2014/15. Wellington: Ministry of Health. Published in December 2014 by the Ministry
More informationNational Lung Cancer Audit outlier policy 2017
National Lung Cancer Audit outlier policy 2017 The National Lung Cancer Audit (NLCA) publishes detailed information on the treatment of lung cancer patients, including the outcome of that treatment. Data
More informationPatient Information Forum
Patient Information Forum Nov 2010 - Update Apologies for cancelling our October meeting (due to unforeseen circumstances). Our next meeting is on 14 December, 9:30am-12:30pm, Seminar Room 2, Cancer Centre,
More informationNational Cancer Peer Review Programme
National Cancer Peer Review Programme Julia Hill Acting Deputy National Co-ordinator What is Cancer Peer Review? A quality assurance process for cancer services. An integral part of Improving Outcomes
More informationCancer Waiting Times. 1 April Adjuvant Radical External Beam Radiotherapy Definitions. Version 1.0
Cancer Waiting Times Adjuvant Radical External Beam Radiotherapy Definitions Version 1.0 1 April 2015 Document Control Document Purpose Definitions for NHS Boards for the adjuvant radical external beam
More informationPancreat ic Cancer UK. policy briefing. A cancer of unmet need: the pancreatic cancer research challenge
Pancreat ic Cancer UK policy briefing A cancer of unmet need: the pancreatic cancer research challenge Introduction Pancreatic Cancer UK s Study for Survival, launched in 2011, marked the first ever comprehensive
More informationWednesday 29 July Management of Pandemic Flu
JOINT TRUST BOARD AND MEMBERSHIP COUNCIL MEETING TITLE Wednesday 29 July 2009 Management of Pandemic Flu PURPOSE To provide a briefing and assurance to the Trust Board and Governors on the actions taken
More informationAppendix E - Summary form Oxaliplatin and capecitabine for the adjuvant treatment of colon cancer table of consultee comments
Oxaliplatin and capecitabine for the adjuvant treatment of colon cancer table of consultee comments Section Consultees Comments Action Objective Roche RCP RCP As far as capecitabine is concerned, the objective
More informationNational Horizon Scanning Centre. Sunitinib (Sutent) for advanced and/or metastatic breast cancer. December 2007
Sunitinib (Sutent) for advanced and/or metastatic breast cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationCommissioning Chemotherapy Services Conference. Issues of consent in systemic therapy
Commissioning Chemotherapy Services Conference Issues of consent in systemic therapy Dr Janine Mansi Consultant Medical Oncologist 28 th November 2017 Introduction Background and context What we have done
More informationAdult Intravenous Systemic Anticancer Therapy (SACT) Section A. SUMMARY of SCHEME QIPP Reference
CA2 Nationally standardised Dose banding for Adult Intravenous Anticancer Therapy (SACT) Scheme Name CA2: Nationally Standardised Dose Banding for Adult Intravenous Systemic Anticancer Therapy (SACT) Section
More informationRichard Watson, Chief Transformation Officer. Dr P Holloway, GP Clinical Lead for Cancer Lisa Parrish, Senior Transformation Lead
GOVERNING BODY Agenda Item No. 08 Reference No. IESCCG 18-02 Date. 23 January 2018 Title Lead Chief Officer Author(s) Purpose Cancer Services Update Richard Watson, Chief Transformation Officer Dr P Holloway,
More informationCancer Services Performance Indicators. Round Report
Cancer Services Performance Indicators Round 1 2015 Report To receive this publication in an accessible format phone (03) 9096 2136, using the National Relay Service 13 36 77 if required, or email cancerplanning@dhhs.vic.gov.au
More informationPrimary Health Networks
Primary Health Networks Drug and Alcohol Treatment Activity Work Plan 2016-17 to 2018-19 Drug and Alcohol Treatment Budget Gippsland When submitting this Activity Work Plan 2016-2018 to the Department
More informationTrends in Cancer Survival in NSW 1980 to 1996
Trends in Cancer Survival in NSW 19 to 1996 Xue Q Yu Dianne O Connell Bruce Armstrong Robert Gibberd Cancer Epidemiology Research Unit Cancer Research and Registers Division The Cancer Council NSW August
More informationStatistical Press Notice NHS referral to treatment (RTT) waiting times data July 2017
Thursday 14 September 2017 Statistical Press Notice NHS referral to treatment (RTT) waiting times data July 2017 NHS England released statistics today on referral to treatment (RTT) waiting times for consultant-led
More informationStatistical Press Notice NHS referral to treatment (RTT) waiting times data August 2017
Thursday 12 October 2017 Statistical Press Notice NHS referral to treatment (RTT) waiting times data August 2017 NHS England released statistics today on referral to treatment (RTT) waiting times for consultant-led
More informationHaemato-oncology Clinical Forum. 20 th June 2013
Haemato-oncology Clinical Forum 20 th June 2013 Welcome Dr Majid Kazmi, LCA Haemato-oncology Pathway Group Chair Purpose of today Provide an update on progress of the LCA to date Identify priorities for
More informationCONSTITUTION SOUTHAMPTON CHILDREN & YOUNG PEOPLE S TRUST PARTNERSHIP
CONSTITUTION SOUTHAMPTON CHILDREN & YOUNG PEOPLE S TRUST PARTNERSHIP 1. AIMS To unify and co-ordinate services for children, young people and families in line with the Children Act 2004 To oversee the
More informationDraft Implementation Plan for Consultation Adult Type 1 Diabetes Guidelines
Draft Implementation Plan for Consultation Adult Type 1 Diabetes Guidelines 1 Adult Type 1 Diabetes Guidelines - Implementation Plan 1. Introduction The following section is a national implementation plan,
More informationGuideline for the Use of Granulocyte Colony Stimulating Factor (G-CSF) for Adults in Oncology and Haematology
(G-CSF) for Adults in Oncology and Haematology For Use in: By: Oncology and Haematology Inpatients and Outpatients Oncologists and Haematologists For: Division responsible for document: Key words: Name
More informationSafeguarding Business Plan
Safeguarding Business Plan 2015-2018 Contents 1. Introduction 2. The Care Act 3. Organisational Development 4. Vision, Values and Strategic Objectives 5. Financial Plan 6. Appendix A Action Plan 7. Appendix
More informationWELSH INFORMATION STANDARDS BOARD
WELSH INFORMATION STANDARDS BOARD DSC Notice: DSCN / 01 Date of Issue: 22 nd March Ministerial / Official Letter: AC/AS/14/080/A9552379 Subject: Diagnostic and Therapy Services Waiting Times Return Sponsor:
More informationA Report of NHS Lanarkshire s Urology and Gynaecology Inpatient Services Consultation
A Report of NHS Lanarkshire s Urology and Gynaecology Inpatient Services Consultation October 2005 You can read and download this document from our website. We can also provide this information: by email
More informationPRESCRIBING BY RADIOGRAPHERS: A VISION PAPER
PRESCRIBING BY RADIOGRAPHERS: A VISION PAPER 1 INTRODUCTION 1.1 The Review of Prescribing, Supply & Administration of Medicines (Crown II) Final Report was submitted to The Secretary of State for Health
More informationGuidance document. Patient and Public Involvement in the planning and development of cancer services
Patient and Public Involvement in the planning and development of cancer services Guidance document The Northern Ireland Cancer Network (NICaN) brings individuals and organisations involved in health care
More informationAllied Healthcare Professionals Module
Allied Healthcare Professionals Module Allied health professionals (AHPs) are key members of today s multidisciplinary healthcare team. They work in partnership with health and social care colleagues across
More informationActivity Report July 2012 June 2013
Urological Cancers Managed Clinical Network Activity Report July 2012 June 2013 Mr Seamus Teahan Consultant Urologist MCN Clinical Lead Tom Kane MCN Manager 1 CONTENTS EXECUTIVE SUMMARY 3 1. INTRODUCTION
More informationClinical Policy: Ramucirumab (Cyramza) Reference Number: CP.HNMC.09 Effective Date: Last Review Date: Line of Business: Medicaid - HNMC
Clinical Policy: (Cyramza) Reference Number: CP.HNMC.09 Effective Date: 07.01.17 Last Review Date: 02.18 Line of Business: Medicaid - HNMC Revision Log See Important Reminder at the end of this policy
More informationNational Cancer Programme. Work Plan 2015/16
National Cancer Programme Work Plan 2015/16 Citation: Ministry of Health. 2015. National Cancer Programme: Work plan 2015/16. Wellington: Ministry of Health. Published in October 2015 by the Ministry of
More informationClinical Policy: Pertuzumab (Perjeta) Reference Number: ERX.SPMN.94
Clinical Policy: (Perjeta) Reference Number: ERX.SPMN.94 Effective Date: 07/16 Last Review Date: 06/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationNATIONAL CANCER CONTROL PROGRAMME NATIONAL STRATEGY FOR THE SAFE ADMINISTATION OF CANCER DRUGS
NATIONAL CANCER CONTROL PROGRAMME NATIONAL STRATEGY FOR THE SAFE ADMINISTATION OF CANCER DRUGS Dr Susan O Reilly MB, FRCPC, FRCPI National Director National Cancer Control Programme IMSN Networking for
More informationWHERE NEXT FOR CANCER SERVICES IN WALES? AN EVALUATION OF PRIORITIES TO IMPROVE PATIENT CARE
WHERE NEXT FOR CANCER SERVICES IN WALES? AN EVALUATION OF PRIORITIES TO IMPROVE PATIENT CARE EXECUTIVE SUMMARY Incidence of cancer is rising, with one in two people born after 1960 expected to be diagnosed
More informationGOVERNING BODY REPORT
GOVERNING BODY REPORT DATE OF MEETING: 20th September 2012 TITLE OF REPORT: KEY MESSAGES: NHS West Cheshire Clinical Commissioning Group has identified heart disease as one of its six strategic clinical
More informationCABINET PROCURING A SUBSTANCE MISUSE & COMMUNITY TREATMENT SERVICE IN RUTLAND
CABINET Report No: 105/2017 PUBLIC REPORT 16 May 2017 PROCURING A SUBSTANCE MISUSE & COMMUNITY TREATMENT SERVICE IN RUTLAND Report of the Director of Public Health Strategic Aim: Safeguarding Key Decision:
More informationSolihull Safeguarding Adults Board & Sub-committees
Solihull Safeguarding Adults Board & Sub-committees 2016 Safeguarding Adults Board Solihull Safeguarding Adults Board [SSAB or the Board] was established in 2008. It is a multi-agency partnership comprising
More informationNumber: III-45 Effective Date: 1 February 2012 Revised Date: November 2016
Page 1 of 8 RATIONALE The BCCA Compassionate Access Program (CAP) application process is intended to address the goals of the BCCA Systemic Therapy Treatment Policy Number III-40. It supports flexibility
More informationCANCER WAITING TIMES (CWTs) A GUIDE (VERSION 8.0)
CANCER WAITING TIMES (CWTs) A GUIDE (VERSION 8.0) This document is to be used to support the monitoring and management of cancer waiting times from 01 July 2012 supporting the implementation of [insert
More informationUnless this copy has been taken directly from the Trust intranet site (Pandora) there is no assurance that this is the most up to date version
Policy No: OP90 Version: 1.0 Name of Policy: Cancer Services Operational Policy Effective From: 02/11/2016 Date Ratified 30/11/2015 Ratified Corporate Management Team Review Date 01/11/2017 Sponsor Director
More informationNational Lung Cancer Audit outlier policy for Wales 2017
National Lung Cancer Audit outlier policy for Wales 2017 The National Lung Cancer Audit (NLCA) publishes detailed information on the treatment of lung cancer patients, including the outcome of that treatment.
More informationSurvival in Teenagers and Young. Adults with Cancer in the UK
Survival in Teenagers and Young Adults with Cancer in the UK Survival in Teenagers and Young Adults (TYA) with Cancer in the UK A comparative report comparing TYA cancer survival with that of children
More informationCancer Transformation Programme
Cancer Transformation Programme Introduction to and supporting documentation for VALUE BASED TRANSFORMATION FUNDING SITE SELECTION November 2016 1 Introduction and Contents The Planning Guidance for 2017-2019
More informationThe next steps
Greater Manchester Hepatitis C Strategy The next steps 2010-2013 Endorsed by GM Director of Public Health group January 2011 Hepatitis Greater Manchester Hepatitis C Strategy 1. Introduction The Greater
More informationPrimary Health Networks
Primary Health Networks Drug and Alcohol Treatment Activity Work Plan 2016-17 to 2018-19 Drug and Alcohol Treatment Budget Murray PHN When submitting this Activity Work Plan 2016-2018 to the Department
More informationThis is supported by more detailed targets and indicators in the Single Outcome Agreement.
7. CANCER PLANNING FRAMEWORK 7.1 Analysis of Local Position 7.1.1 The CHP has a key role to play in the delivery of the cancer planning framework. Local planning for cancer services is co-ordinated through
More information2.2 The primary roles and responsibilities of the Committee are to:
Edinburgh Child Protection Constitution 1. Introduction 1.1 This document sets out the governance arrangements established to promote the delivery of integrated, high quality child protection services
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Trastuzumab (Herceptin), Trastuzumab-dkst (Ogivri) Reference Number: CP.PHAR.228 Effective Date: 07.01.18 Last Review Date: 05.18 Line of Business: Oregon Health Plan Coding Implications
More informationReferral to treatment (RTT) waiting times statistics for consultant-led elective care 2014 Annual Report
Referral to treatment (RTT) waiting times statistics for consultant-led elective care 2014 Annual Report 1 Referral to treatment (RTT) waiting times statistics for consultant-led elective care 2014 Annual
More informationFuture Direction for Cancer Registries
Future Direction for Cancer Registries Sally Vernon Head of Quality and Analysis Eastern Cancer Registry and Information Centre sally.vernon@ecric.nhs.uk In Ye Olde Days. 8 regional cancer registries Variation
More informationPrimary Health Networks
Primary Health Networks Drug and Alcohol Treatment Activity Work Plan 2016-17 to 2018-19 Drug and Alcohol Treatment Budget Murray PHN When submitting this Activity Work Plan 2016-2018 to the Department
More informationNorth of England Cancer Network. Policies and Procedures. Standards for the Safe Use of Oral Anticancer Medicines
\ North of England Cancer Network Policies and Procedures Standards for the Safe Use of Oral Anticancer Medicines NECN Oral Anticancer medicine Policy version 1.6 Page 1 of 17 Issue Date: Feb 2017 Contents
More informationPerjeta (pertuzumab)
Perjeta (pertuzumab) Line(s) of Business: HMO; PPO; QUEST Integration Medicare Advantage Original Effective Date: 10/01/2015 Current Effective Date: 01/01/201809/16/2018 POLICY A. INDICATIONS The indications
More informationTrust Board Meeting in Public: Wednesday 11 July 2018 TB
Trust Board Meeting in Public: Wednesday 11 July 2018 Title Integrated Performance Report: Month 2 Status History For information. The report provides a summary of the Trust s performance against a range
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Trastuzumab, as monotherapy and in combination with a taxane, for the treatment of metastatic breast cancer (to include
More informationPrimary Health Networks
Primary Health Networks Drug and Alcohol Treatment Activity Work Plan 2016-17 to 2018-19 Hunter New England & Central Coast Please note: This Activity Work Plan was developed in response to the HNECC PHN
More informationShared Care Pathway for Soft Tissue Sarcomas Presenting to Site Specialised MDTs. Gynaecological sarcomas Version 1
Shared Care Pathway for Soft Tissue Sarcomas Presenting to Site Specialised MDTs Gynaecological sarcomas Version 1 Background This guidance is to provide direction for the management of patients with sarcomas
More informationDear Colleague GENERAL OPHTHALMIC SERVICES OPTOMETRY INDEPENDENT PRESCRIBING. Summary
NHS: PCA(O)(2013)4 Health and Social Care Integration Directorate Primary Care Division Dear Colleague GENERAL OPHTHALMIC SERVICES OPTOMETRY INDEPENDENT PRESCRIBING Summary 1. This letter advises NHS Boards
More informationabcdefghijklmnopqrstu
CMO and Public Health Directorate Health Improvement Strategy Division Dear Colleague Scottish Abdominal Aortic Aneurysm Screening Programme This CEL outlines the plan for the implementation of the AAA
More informationHaematology, Oncology and Palliative Care Directorate.
Anticancer Treatment for Administration on the Somerset Mobile Chemotherapy Unit The table below details the suitability of different types of anticancer treatment for administration on the Somerset Mobile
More informationNHS. Northern and Yorkshire Cancer Registry and Information Service
NHS Northern and Yorkshire Cancer Registry and Information Service Northern and Yorkshire Cancer Networks A Report on Incidence and Management for the Main Sites of Cancer ACKNOWLEDGEMENTS Acknowledgements
More informationHorizon Scanning Centre November Vinflunine (Javlor) monotherapy for advanced breast cancer SUMMARY NIHR HSC ID: 7887
Horizon Scanning Centre November 2012 Vinflunine (Javlor) monotherapy for advanced breast cancer SUMMARY NIHR HSC ID: 7887 This briefing is based on information available at the time of research and a
More informationNational Horizon Scanning Centre. Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy
Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy December 2007 This technology summary is based on information available at the time of research and
More informationGuideline for the referral to the Late Effects Multi Disciplinary Team
Guideline for the referral to the Late Effects Multi Disciplinary Team Version History Version Date Summary of Change\Process 0.1 July 2010 Reviewed and approved by West Midlands Children s Cancer Network
More informationGOVERNING BODY MEETING in Public 22 February 2017 Agenda Item 3.4
GOVERNING BODY MEETING in Public 22 February 2017 Paper Title Purpose of paper Redesign of Services for Frail Older People in Eastern Cheshire To seek approval from Governing Body for the redesign of services
More informationWe are currently recruiting new members to advisory groups for the following research programmes:
Information for applicants to join NIHR as an advisory group member: HTA Programme Topic Identification, Development and Evaluation (TIDE) panel Chairs 1. Background information The goal of the National
More informationBASED AT INVERCLYDE ROYAL HOSPITAL
SPECIALTY DENTIST IN ORTHODONTICS BASED AT INVERCLYDE ROYAL HOSPITAL INFORMATION PACK REF: 23355D CLOSING DATE: 15 TH JULY 2011 SUMMARY INFORMATION POST: SPECIALTY DENTIST IN ORTHODONTICS BASE: INVERCLYDE
More informationActivity Report March 2013 February 2014
West of Scotland Cancer Network Skin Cancer Managed Clinical Network Activity Report March 2013 February 2014 Dr Girish Gupta Consultant Dermatologist MCN Clinical Lead Tom Kane MCN Manager West of Scotland
More informationStandard Operating Procedure: Early Intervention in Psychosis Access Times
Corporate Standard Operating Procedure: Early Intervention in Psychosis Access Times Document Control Summary Status: New Version: V1.0 Date: Author/Owner: Rob Abell, Senior Performance Development Manager
More informationVictorian Paediatric Oncology Situational Analysis & Workforce Requirements
- Victorian Paediatric Oncology Situational Analysis & Workforce Requirements 2012-2026 SUMMARY REPORT May 2013 1 Contents Executive summary...3 1. Introduction...6 2. Project method...8 2.1 Estimating
More informationTechnology appraisal guidance Published: 18 July 2018 nice.org.uk/guidance/ta531
Pembrolizumab for untreated PD- L1-positive metastatic non-small-cell lung cancer Technology appraisal guidance Published: 18 July 2018 nice.org.uk/guidance/ta531 NICE 2018. All rights reserved. Subject
More information